These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9566425)

  • 1. Olanzapine can worsen parkinsonism.
    Jiménez-Jiménez FJ; Tallón-Barranco A; Ortí-Pareja M; Zurdo M; Porta J; Molina JA
    Neurology; 1998 Apr; 50(4):1183-4. PubMed ID: 9566425
    [No Abstract]   [Full Text] [Related]  

  • 2. Olanzapine and neuroleptic malignant syndrome.
    Tofler I
    Psychosomatics; 2002; 43(6):505-6; author reply 506. PubMed ID: 12444237
    [No Abstract]   [Full Text] [Related]  

  • 3. Olanzapine: extrapyramidal side effects in the elderly.
    Granger AS; Hanger HC
    Aust N Z J Med; 1999 Jun; 29(3):371-2. PubMed ID: 10868502
    [No Abstract]   [Full Text] [Related]  

  • 4. The economic consequences of a drug-drug interaction.
    Shad MU; Marsh C; Preskorn SH
    J Clin Psychopharmacol; 2001 Feb; 21(1):119-20. PubMed ID: 11199940
    [No Abstract]   [Full Text] [Related]  

  • 5. Worsening of motor features of parkinsonism with olanzapine.
    Molho ES; Factor SA
    Mov Disord; 1999 Nov; 14(6):1014-6. PubMed ID: 10584679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
    Rudolf J; Ghaemi M; Schmülling S
    Eur Psychiatry; 1999 Oct; 14(6):356-7. PubMed ID: 10572371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between olanzapine and haloperidol.
    Gomberg RF
    J Clin Psychopharmacol; 1999 Jun; 19(3):272-3. PubMed ID: 10350035
    [No Abstract]   [Full Text] [Related]  

  • 8. Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.
    Onofrj M; Thomas A; Bonanni L; Iacono D; Gambi F
    Neurol Sci; 2000 Aug; 21(4):209-15. PubMed ID: 11214659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine usage associated with neuroleptic malignant syndrome.
    Philibert RA; Adam LA; Frank FM; Carney-Doebbeling C
    Psychosomatics; 2001; 42(6):528-9. PubMed ID: 11815691
    [No Abstract]   [Full Text] [Related]  

  • 10. Olanzapine/risperidone and diabetes risk.
    Lee DW; Fowler RB
    J Clin Psychiatry; 2003 Jul; 64(7):847-8; author reply 848. PubMed ID: 12934988
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute hepatocellular-cholestatic liver injury after olanzapine therapy.
    Jadallah KA; Limauro DL; Colatrella AM
    Ann Intern Med; 2003 Feb; 138(4):357-8. PubMed ID: 12585842
    [No Abstract]   [Full Text] [Related]  

  • 12. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.
    Friedman J
    Neurology; 1998 Apr; 50(4):1195-6. PubMed ID: 9566437
    [No Abstract]   [Full Text] [Related]  

  • 13. Olanzapine and pancreatitis.
    Hagger R; Brown C; Hurley P
    Br J Psychiatry; 2000 Dec; 177():567. PubMed ID: 11102343
    [No Abstract]   [Full Text] [Related]  

  • 14. Olanzapine-associated priapism.
    Gordon M; de Groot CM
    J Clin Psychopharmacol; 1999 Apr; 19(2):192. PubMed ID: 10211928
    [No Abstract]   [Full Text] [Related]  

  • 15. Olanzapine-induced agranulocytosis: a case report and review of the literature.
    Tolosa-Vilella C; Ruiz-Ripoll A; Mari-Alfonso B; Naval-Sendra E
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):411-4. PubMed ID: 11817522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine toxicity in unconjugated hyperbilirubinaemia (Gilbert's syndrome).
    Martín-Escudero JC; Dueñas-Laíta A; Pérez-Castrillón JL; Herreros-Fernández V
    Br J Psychiatry; 2003 Mar; 182():267. PubMed ID: 12611795
    [No Abstract]   [Full Text] [Related]  

  • 17. Olanzapine and rhabdomyolysis.
    Shuster J
    Nursing; 2000 Sep; 30(9):87. PubMed ID: 11022553
    [No Abstract]   [Full Text] [Related]  

  • 18. [Neuroleptic malignant syndrome and atypical antipsychotics].
    Canora Lebrato J; Bermúdez García JM; Alvarez García ML; Rico Irles J
    Med Clin (Barc); 2000 Sep; 115(7):279. PubMed ID: 11013157
    [No Abstract]   [Full Text] [Related]  

  • 19. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.
    Wolters EC; Jansen EN; Tuynman-Qua HG; Bergmans PL
    Neurology; 1996 Oct; 47(4):1085-7. PubMed ID: 8857751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine: weight gain and therapeutic efficacy.
    Gupta S; Droney T; Al-Samarrai S; Keller P; Frank B
    J Clin Psychopharmacol; 1999 Jun; 19(3):273-5. PubMed ID: 10350036
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.